SCHEMBL135106

SCHEMBL135106

O=C(O)[C@@H]1CCC(c2ccccc2)N1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 13/20 0.56
SCN3A Q9NY46 8/20 0.56
DPP4 P27487 1/20 0.52
SCN1A P35498 1/20 0.44
SCN4A P35499 1/20 0.44
SCN7A Q01118 1/20 0.44
SCN5A Q14524 1/20 0.44
SCN9A Q15858 1/20 0.44
SCN2A Q99250 1/20 0.44
SCN8A Q9UQD0 1/20 0.44
SCN10A Q9Y5Y9 1/20 0.44
S1PR4 O95977 2/20 0.43
S1PR1 P21453 2/20 0.43
S1PR5 Q9H228 2/20 0.43
S1PR3 Q99500 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2B6 P20813 1/20 0.43
MAOB P27338 1/20 0.43
CYP2C19 P33261 1/20 0.43
AKR1C3 P42330 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8513273 1.00 KCNH2 (0.56) KCNH2SCN3ADPP4SCN1ASCN4A
SCHEMBL5696388 1.00 KCNH2 (0.56) KCNH2SCN3ADPP4SCN1ASCN4A
SCHEMBL197791 1.00 KCNH2 (0.56) KCNH2SCN3ADPP4SCN1ASCN4A
SCHEMBL197425 1.00 KCNH2 (0.56) KCNH2SCN3ADPP4SCN1ASCN4A
SCHEMBL135105 1.00 KCNH2 (0.56) KCNH2SCN3ADPP4SCN1ASCN4A
SCHEMBL1226045 1.00 KCNH2 (0.56) KCNH2SCN3ADPP4SCN1ASCN4A
Hydrochloric Acid SCHEMBL5513962 0.98 KCNH2 (0.55) KCNH2SCN3ADPP4SCN1ASCN4A
Hydrochloric Acid SCHEMBL11235696 0.98 KCNH2 (0.55) KCNH2SCN3ADPP4SCN1ASCN4A
Hydrochloric Acid SCHEMBL8870650 0.98 KCNH2 (0.55) KCNH2SCN3ADPP4SCN1ASCN4A
Hydrochloric Acid SCHEMBL8870646 0.98 KCNH2 (0.55) KCNH2SCN3ADPP4SCN1ASCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1045 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10800829-B2 Optogenetic probes for measuring membrane potential PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-10-13 US claimed
WO-2019011879-A1 THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME HENNING RAINER (CH) 2019-01-17 WO claimed
US-20160076058-A1 HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE GENOMATICA, INC. 2016-03-17 US claimed
US-8088890-B2 Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2012-01-03 US claimed
EP-2334324-A2 BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY Fibrex Medical Research & Development GmbH (AT) 2011-06-22 EP claimed
EP-2328925-A1 PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION Fibrex Medical Research & Development GmbH (AT) 2011-06-08 EP claimed
US-7884074-B2 Compounds and methods for prevention and/or treatment of inflammation using the same Ikaria Development Subsidiary Two, LLC (US) 2011-02-08 US claimed
EP-2274328-A1 PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION Fibrex Medical Research & Development GmbH (AT) 2011-01-19 EP claimed
US-20100099602-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2010-04-22 US claimed
WO-2010043972-A2 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2010-04-22 WO claimed
WO-2010034041-A1 PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2010-04-01 WO claimed
US-20100081787-A1 PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2010-04-01 US claimed
EP-2160460-A2 HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE LS9, Inc. (US) 2010-03-10 EP claimed
US-20090286739-A1 PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2009-11-19 US claimed
WO-2009137850-A1 PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2009-11-19 WO claimed
WO-2008147781-A2 HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE LS9, INC. (US) 2008-12-04 WO claimed
US-20260091067-A1 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MARVELBIOME INC (US) 2026-04-02 US disclosed
US-12584119-B2 Variant alpha-amylases having amino acid substitutions that lower the PKA of the general acid DANISCO US INC (US) 2026-03-24 US disclosed
EP-0476044-A4 TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS 1992-07-01 EP disclosed
EP-0476044-A1 TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. CEPHALON INC (US) 1992-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099602-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY HIF1AN, HIF1A, EGLN3 KCNH2 1582/4885SCN3A 1347/4885DPP4 975/4885
US-20260091067-A1 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES IAPP, GPR119, FAHD1 KCNH2 651/4885SCN3A 2418/4885DPP4 1133/4885
US-20100081787-A1 PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION NGLY1, GHRHR, GHSR KCNH2 2693/4885SCN3A 200/4885DPP4 3514/4885
US-12584119-B2 Variant alpha-amylases having amino acid substitutions that lower the PKA of the general acid AMY1A, AMY2A, PRKCSH KCNH2 1542/4885SCN3A 478/4885DPP4 666/4885
US-20090286739-A1 PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION NPR3, RXFP3, RXFP1 KCNH2 3036/4885SCN3A 370/4885DPP4 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.